MIS-C Comparative Effectiveness Study

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

December 22, 2023

Study Completion Date

July 31, 2025

Conditions
Multisystem Inflammatory Syndrome-Children
Interventions
DRUG

Infliximab

Infliximab will be administered as a single IV dose of 10 mg/kg over 2 hours.

DRUG

Anakinra

Anakinra will be administered at a dose of 8 mg/kg/day IV or SQ with 100 mg every 6 hours as the max dose. This is discontinued with a taper during the hospitalization over 2-4 days once a patient is stable with significantly improved clinical course and laboratory profile.

DRUG

Methylprednisolone

Methylprednisilone (steroids) will be administered as 2 mg/kg IV or orally divided every 12 hours. At the time of hospital discharge the patient will be given a steroid taper that will take at least 3 weeks to complete.

Trial Locations (2)

48201

Children's Hospital Michigan, Detroit

92123

Rady Children's Hospital, San Diego

All Listed Sponsors
collaborator

Children's Hospital of Michigan

OTHER

lead

University of California, San Diego

OTHER